O	0	5	Phase
O	6	9	III
O	10	20	randomized
O	21	32	equivalence
O	33	38	trial
O	39	41	of
O	42	47	early
O	48	54	breast
O	55	61	cancer
O	62	72	treatments
O	73	77	with
O	78	80	or
O	81	88	without
B-intervention	89	97	axillary
I-intervention	98	107	clearance
O	108	110	in
O	111	115	post
O	115	116	-
O	116	126	menopausal
O	127	135	patients
O	136	143	results
O	144	149	after
O	150	151	5
O	152	157	years
O	158	160	of
O	161	167	follow
O	167	168	-
O	168	170	up
O	170	171	.

O	172	180	Axillary
O	181	186	lymph
O	187	191	node
O	192	201	clearance
O	202	203	(
O	203	207	ALNC
O	207	208	)
O	209	217	improves
O	218	230	locoregional
O	231	238	control
O	239	242	and
O	243	251	provides
O	252	262	prognostic
O	263	274	information
O	275	278	for
O	279	284	early
O	285	291	breast
O	292	298	cancer
O	299	308	treatment
O	308	309	,
O	310	313	but
O	314	321	effects
O	322	324	on
O	325	333	survival
O	334	337	are
O	338	351	controversial
O	351	352	.

O	353	357	This
O	358	369	multicentre
O	369	370	,
O	371	381	randomized
O	382	391	pragmatic
O	392	403	equivalence
O	404	409	trial
O	410	418	compares
O	419	427	outcomes
O	428	431	for
O	432	436	post
O	436	437	-
O	437	447	menopausal
O	448	453	early
O	454	462	invasive
O	463	469	breast
O	470	476	cancer
O	477	485	patients
O	486	491	after
O	492	504	locoregional
O	505	514	treatment
O	515	519	with
O	520	524	ALNC
O	525	528	and
O	529	537	adjuvant
O	538	547	therapies
O	548	550	to
O	551	559	outcomes
O	560	565	after
O	566	578	locoregional
O	579	588	treatment
O	589	596	without
O	597	601	ALNC
O	602	605	and
O	606	614	adjuvant
O	615	624	therapies
O	624	625	.

O	626	630	From
O	631	635	1995
O	635	636	-
O	636	640	2005
O	640	641	,
O	642	647	women
O	648	652	aged
B-age	653	654	≥
I-age	655	657	50
I-age	658	663	years
B-eligibility	664	668	with
I-eligibility	669	674	early
I-eligibility	675	681	breast
I-eligibility	682	688	cancer
I-eligibility	689	690	(
I-eligibility	690	695	tumor
I-eligibility	696	697	≤
I-eligibility	698	700	10
I-eligibility	701	703	mm
I-eligibility	703	704	)
I-eligibility	705	708	and
I-eligibility	709	719	clinically
I-eligibility	719	720	-
I-eligibility	720	728	negative
I-eligibility	729	737	axillary
I-eligibility	738	743	nodes
O	744	748	were
O	749	759	randomized
O	760	762	to
O	763	770	receive
O	771	780	treatment
O	781	785	with
O	786	790	ALNC
O	791	792	(
O	792	794	Ax
O	794	795	)
O	796	798	or
B-control	799	806	without
I-control	807	808	(
I-control	808	810	no
I-control	810	811	-
I-control	811	813	Ax
I-control	813	814	)
O	814	815	.

O	816	824	Adjuvant
O	825	834	therapies
O	835	839	were
O	840	850	prescribed
O	851	860	according
O	861	863	to
O	864	872	hormonal
O	873	881	receptor
O	882	888	status
O	889	892	and
O	893	903	individual
O	904	916	histological
O	917	924	results
O	924	925	.

O	926	929	The
O	930	937	primary
O	938	946	endpoint
O	947	950	was
B-outcome-Measure	951	958	overall
I-outcome-Measure	959	967	survival
I-outcome-Measure	968	969	(
I-outcome-Measure	969	971	OS
I-outcome-Measure	971	972	)
O	972	973	;
O	974	983	secondary
O	984	993	endpoints
O	994	998	were
B-outcome-Measure	999	1004	event
I-outcome-Measure	1004	1005	-
I-outcome-Measure	1005	1009	free
I-outcome-Measure	1010	1018	survival
I-outcome-Measure	1019	1020	(
I-outcome-Measure	1020	1023	EFS
I-outcome-Measure	1023	1024	)
O	1025	1028	and
B-outcome-Measure	1029	1039	functional
I-outcome-Measure	1040	1048	outcomes
O	1048	1049	.

O	1050	1053	The
O	1054	1059	trial
O	1060	1063	was
O	1064	1074	terminated
O	1075	1078	due
O	1079	1081	to
O	1082	1086	lack
O	1087	1089	of
O	1090	1101	equivalence
O	1102	1105	and
O	1106	1109	low
O	1110	1117	accrual
O	1118	1123	after
O	1124	1129	first
O	1130	1137	interim
O	1138	1146	analyses
O	1146	1147	.

O	1148	1159	NCT00210236
O	1159	1160	.

O	1161	1163	Of
B-total-participants	1164	1167	625
O	1168	1176	patients
O	1176	1177	,
B-control-participants	1178	1181	297
O	1182	1184	no
O	1184	1185	-
O	1185	1187	Ax
O	1188	1191	and
B-intervention-participants	1192	1195	310
O	1196	1198	Ax
O	1199	1207	patients
O	1208	1212	were
O	1213	1223	maintained
O	1224	1227	for
O	1228	1233	final
O	1234	1237	per
O	1237	1238	-
O	1238	1246	protocol
O	1247	1255	analyses
O	1255	1256	.

B-outcome	1257	1259	OS
O	1260	1263	and
B-outcome	1264	1267	EFS
O	1268	1270	at
O	1271	1275	five
O	1276	1281	years
O	1282	1286	were
O	1287	1290	not
O	1291	1301	equivalent
O	1302	1303	(
O	1303	1305	Ax
O	1306	1308	vs
O	1308	1309	.
O	1310	1312	no
O	1312	1313	-
O	1313	1315	Ax
O	1315	1316	:
B-iv-bin-percent	1317	1319	98
I-iv-bin-percent	1319	1320	%
O	1321	1323	vs
O	1323	1324	.
B-cv-bin-percent	1325	1327	94
I-cv-bin-percent	1327	1328	%
O	1329	1332	and
B-iv-bin-percent	1333	1335	96
I-iv-bin-percent	1335	1336	%
O	1337	1339	vs
O	1339	1340	.
B-cv-bin-percent	1341	1343	90
I-cv-bin-percent	1343	1344	%
O	1345	1357	respectively
O	1357	1358	)
O	1358	1359	.

B-outcome	1360	1370	Recurrence
O	1371	1374	was
O	1375	1381	higher
O	1382	1385	for
O	1386	1388	no
O	1388	1389	-
O	1389	1391	Ax
O	1391	1392	,
O	1393	1405	particularly
O	1406	1408	in
O	1409	1412	the
O	1413	1418	first
O	1419	1423	five
O	1424	1429	years
O	1430	1435	after
O	1436	1443	surgery
O	1443	1444	.

B-outcome	1445	1453	Axillary
I-outcome	1454	1459	nodes
I-outcome	1460	1464	were
I-outcome	1465	1473	positive
O	1474	1477	for
B-iv-bin-percent	1478	1480	14
I-iv-bin-percent	1480	1481	%
O	1482	1484	Ax
O	1485	1493	patients
O	1494	1497	but
O	1498	1502	only
B-cv-bin-percent	1503	1504	2
I-cv-bin-percent	1504	1505	%
O	1506	1508	no
O	1508	1509	-
O	1509	1511	Ax
O	1512	1520	patients
O	1521	1532	experienced
O	1533	1541	axillary
O	1542	1546	node
O	1547	1557	recurrence
O	1557	1558	.

B-outcome	1559	1569	Functional
I-outcome	1570	1581	impairments
O	1582	1586	were
O	1587	1594	greater
O	1595	1600	after
O	1601	1605	ALNC
O	1605	1606	.

O	1607	1610	Our
O	1611	1618	results
O	1619	1623	fail
O	1624	1626	to
O	1627	1638	demonstrate
O	1639	1650	equivalence
O	1651	1653	of
O	1654	1662	outcomes
O	1663	1667	when
O	1668	1672	ALNC
O	1673	1675	is
O	1676	1683	omitted
O	1684	1688	from
O	1689	1693	post
O	1693	1694	-
O	1694	1704	menopausal
O	1705	1710	early
O	1711	1717	breast
O	1718	1724	cancer
O	1725	1732	patient
O	1733	1742	treatment
O	1742	1743	.

O	1744	1751	However
O	1752	1755	the
O	1756	1759	low
O	1760	1772	locoregional
O	1773	1783	recurrence
O	1784	1789	rates
O	1790	1797	warrant
O	1798	1805	further
O	1806	1817	examination
O	1818	1822	over
O	1823	1824	a
O	1825	1831	longer
O	1832	1840	duration
O	1840	1841	,
O	1842	1844	in
O	1845	1855	particular
O	1856	1858	to
O	1859	1867	consider
O	1868	1875	whether
O	1876	1881	these
O	1882	1887	would
O	1888	1894	impact
O	1895	1897	on
O	1898	1906	survival
O	1906	1907	.
